Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Vaccinex Inc VCNX

Healthcare Biotechnology
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VCNX)

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

GlobeNewswire April 2, 2024

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire March 27, 2024

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

GlobeNewswire February 21, 2024

Vaccinex, Inc. Announces Reverse Stock Split

GlobeNewswire February 15, 2024

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

GlobeNewswire February 7, 2024

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule

GlobeNewswire December 4, 2023

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

GlobeNewswire October 31, 2023

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

GlobeNewswire October 26, 2023
View More News ››

Opinion & Analysis (NDAQ:VCNX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VCNX)

(VCNX) Trading Advice

News; $VCNX (VCNX) Trading Advice2024-03-08 11:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method....
whytestocks - March 8, 2024
View more Bullboard ››

International Lithium Corp.

International Lithium Corp.

International Lithium Corp has lithium exploration properties located in Canada and Ireland. Its primary strategic focus is ...
View More »